FDA refuses to approve GSK’s respiratory drug mepolizumab for COPD
The British pharma giant is seeking approval for mepolizumab as an add-on treatment to inhaled corticosteroid-based maintenance treatment for reducing exacerbations in patients with COPD guided by blood
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.